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Abstract: The active metabolite of the novel immunosuppressive agent leflunomide has 
been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme 
catalyzes the fourth step in de novo pyrimidine biosynthesis. Self-organizing molecular 
field  analysis  (SOMFA),  a  simple  three-dimensional  quantitative  structure-activity 
relationship (3D-QSAR) method is used to study the correlation between the molecular 
properties and the biological activities of a series of analogues of the active metabolite. The 
statistical results, cross-validated rCV
2 (0.664) and non cross-validated r
2 (0.687), show a 
good  predictive  ability.  The  final  SOMFA  model  provides  a  better  understanding  of 
DHODH inhibitor-enzyme interactions, and may be useful for further modification and 
improvement of inhibitors of this important enzyme. 
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1. Introduction  
The dihydroorotate dehydrogenase (DHODH) ia an essential mitochondrial enzyme that catalyzes 
the  flavin  mononucleotide-dependent  formation  of  orotic  acid,  a  key  step  in  de  novo  pyrimidine 
biosynthesis [1,2]. This enzyme is an attractive chemotherapeutic target in various pathogens, such as 
Plasmodium falciparum and Helicobacter pylori, and for the treatment of human disease, such as 
cancer, malaria and rheumatoid arthritis [3–5]. 
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All potent inhibitors of DHODH published to date bind to the putative ubiquinone binding channel 
and display beneficial immunosuppressive and antiproliferative activities, shown to be most pronounced 
during T-cell proliferation [6]. Brequinar and leflunomide are two examples of low-molecular weight 
inhibitors of DHODH that have been in clinical development [7–9]. Leflunomide is now marketed as a 
treatment  for  rheumatoid  arthritis.  A  series  of  analogues  of  the  active  metabolite  of  an 
immunosuppressive agent leflunomide have also been synthesized and found to inhibit DHODH [10].  
Quantitative structure-activity relationships are the most important applications of chemometrics, 
giving useful information for the design of new compounds acting on a specific target. Quantitative 
structure-activity relationship (QSAR) attempts to find a consistent relationship between biological 
activity and molecular properties. Thus, QSAR models can be used to predict the activity of new 
compounds. Although there has been much interest in synthesis of various inhibitors of DHODH, there 
have been few QSAR studies of DHODH inhibitors [10–13]. Kuo [10] and Ren [11] have even reported 
the structure-activity relationships (SAR) and quantitative structure-activity relationship (2D-QSAR) of 
this series of analogues, respectively.  
The self-organizing molecular field analysis (SOMFA) [14] is a simple 3D-QSAR technique, which 
has been developed by Robinson et al. The method has similarities to both comparative molecular field 
analysis (CoMFA) [15] and molecular similarity studies. Like CoMFA, a grid-based approach is used; 
however, SOMFA only uses steric and electrostatic maps, which are related to interaction energy maps, 
no probe interaction energies need to be evaluated. The weighting procedure of the grid points by 
Mean-Centered-activity  is  an  important  ingredient  of  the  SOMFA  procedure.  Like  the  similarity 
methods, it is the intrinsic molecular properties, such as the molecular shape and electrostatic potential, 
which are used to develop the QSAR models. 
A  SOMFA  model  could  suggest  a  method  of  tackling  the  all-important  alignment,  which  all  
3D-QSAR  methods  have  faced.  The  inherent  simplicity  of  this  method  allows  the  possibility  of 
aligning the training compounds as an integral part of the model derivation process and of aligning 
prediction compounds to optimize their predicted activities. 
In a recent study, leflunomide has been found to exhibit some dose-dependent side effects in a small 
number of patients [16]. The purpose of this paper is to describe the application of self-organizing 
molecular field analysis, SOMFA, on the analogues of the active metabolite of leflunomide, to analyze 
the three-dimensional quantitative structure-activity relationships (3D-QSAR) and to determine the 
structural requirements of this series of analogues for optimum activity. The 3D-QSAR together with 
the modeling studies will provide a more precise elucidation of the molecular forces involved in the 
DHODH inhibitor-enzyme interactions, and may be useful for further modification and improvement 
of inhibitors of this important enzyme. 
2. Materials and Methods  
2.1. Data Sets 
The biological activities of analogues of the active metabolite of leflunomide were taken from the 
papers by Kuo et al. [10]. Not every compound from Kuo’s paper was included in the 3D-QSAR 
analysis because of the lack of parameters (6 compounds) and the exact IC50 values (IC50  10
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6 compounds). All analogues were classified into two subgroups according to the substituents at their 
two different positions, 42 aromatic substituted analogues and 12 side chain 3-substituted analogues.  
Fifty-three analogues are divided into two sets. The training set of 42 molecules with structures are 
shown  in  Table  1  and  their  enzyme  inhibitory  activities  expressed  as  log(1/IC50)  are  shown  in  
Section 3. The predictive power of the models is evaluated using a test set of 11 molecules whose 
structures are also shown in Table 1 and activities will be shown in Section 3. 
Table 1. Chemical structures of active metabolite analogues of leflunomide. 
N
H
O OH
N
R1
R2 R3  
Compd 
No. 
R1  R2  R3 
Compd 
No. 
R1  R2  R3 
1  H  H  H  29  Cl  CH3  H 
2  CH3  H  H  30*  Cl  H  CH3 
3  CF3  H  H  31  CH3  Cl  H 
4  H  CF3  H  32  Br  CH3  H 
5*  Cl  H  H  33  CN  CH3  H 
6  H  Cl  H  34  CF3S  CH3  H 
7  H  H  Cl  35*  CF3O  CH3  H 
8  Br  H  H 
36 
S
 
H  H  9  CN  H  H 
10*  -CH2CN  H  H 
11  CF3S  H  H 
37  O
 
H  H  12  CF3SO  H  H 
13  CF3SO2  H  H 
14  CH3S  H  H 
38  C
O
Cl
 
H  H  15*  CH3SO  H  H 
16  CH3SO2  H  H 
17  CF3O  H  H 
39  Cl
 
H  H  18  CH3O  H  H 
19  OH  H  H 
20*  NO2  H  H 
40* 
H2
C
H2
C
 
H  H  21  H2N  H  H 
22  CH3CO  H  H 
23  H2NCO  H  H 
41  F
 
H  H  24  HOOC-  H  H 
25*  CH3O2C-  H  H 
26  CF3  CH3  H 
42 
 
H  H  27  CF3  C2H5  H 
28  C2F5  CH3  H 
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Table 1. Cont. 
N
H
R
O OH
N
F3C
 
Compd 
 No.  R  Compd  
No.  R 
43  -CH3  48 
 
3 
 
49 
 
44 
 
50* 
 
45* 
 
51 
 
46 
O
 
52 
CH3
 
47 
O
 
53* 
 
*-Test set. 
Two  sets  of  molecules  are  selected  in  order  to  elucidate  convenient  models  for  the  predictive 
discrimination between these various activities. 
2.2. Molecular Modeling and Alignment 
The three-dimensional structures of the analogues were constructed with the ArgusLab 4.01 [17] 
according to the conformations of active metabolite A771726 (Compound 43) from PDB 1d3h [18], 
running on an AMD Athlon 64 X2 Dual Core Processor 3600 + CPU/Microsoft Win XP platform. 
Unless otherwise indicated, parameters are default. Full geometry optimizations are performed first 
by molecular mechanics MM2, and then optimized by PM3 semi-empirical method in the ArgusLab 
software. The final active conformations are then performed RMS overlapping and fitted with the 
compound  43  as  a  reference.  Two  different  alignments  are  selected  to  define  overlap.  The  atom 
numbers and corresponding sequence for each alignment are defined in Table 2. 
Table  2.  The  atom  numbers  and  three-atom  sequences  defining  the  two  alignments 
(compound 43 is used to define the atom number). 
N
H
CH3
O OH
N
F3C
1 2
3
4 5
 
Alignment No.  1st atom  2nd atom  3rd atom 
1  1  2  3 
2  2  4  5 
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According to two alignment of the final active conformations of analogues, these compounds are 
then  performed  SOMFA  analysis.  The  superposition  of  active  analogues  structures  according  to 
alignment 1 (considering phenyl ring similarity) has been shown in Figure 1, the superposition of 
active analogues according to the alignment 2 (considering all skeleton similarity) has also been shown 
in Figure 2. Using VEGA software [19], the final overlayed geometries are converted into CSSR file 
format, the only file format which the SOMFA2 program can accept to process a SOMFA analysis. 
Figure 1. Superposition of active analogues structures according to alignment 1. 
 
Figure 2. Superposition of active analogues structures according to alignment 2. 
 
2.3. SOMFA 3D-QSAR Models 
In the SOMFA study a 40 ×  40 ×  40 Å grid originating at (−20, −20, −20) with a resolution of 0.5 Å, 
is generated around the aligned compounds, and all compounds have been assigned charges by the 
MNDO  hamiltonian semi-empirical  method  according to  our  previous works [20,21].  12 different 
models using different enzyme, compound subgroups and alignment under exploration are presented in 
Table 3. 
For all of the studied compounds, shape and electrostatic potential are generated. To sum up the 
predictive power of these two properties into one final model, we combine their individual predictions 
using  a  weighted  average  of  the  shape  and  electrostatic  potential  based  QSAR,  using  a  mixing 
coefficient (c1) as illustrated in Equation 1 [14]. 
Activity = c1Activityshape + (1 − c1)ActivityESP  (1)  
Clearly, multiproperty predictions could have been obtained through multiple linear regression. Int. J. Mol. Sci. 2011, 12                       
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Using Equation 1 instead gives greater insight into the resultant model by allowing the study of the 
variation in predictive power with different values of c1. 
With the highest value of r
2, the SOMFA models then are derived by the partial least squares (PLS), 
implemented in SPSS software [22] with cross-validation. 
The predictive ability of the model is quantitated in terms of rCV
2 which is defined in Equation 2. 
rCV
2 = (SD − PRESS)/SD  (2)  
where PRESS = (Ypred − Yactual) and SD = (Yactual − Ymean). 
SD is the sum of squares of the difference between the observed values and their meaning and 
PRESS is the prediction error sum of squares. The final models are constructed by a conventional 
regression analysis with the optimum value of mixing coefficient (c1) equal to that yielding the highest 
r
2 and rCV
2 value according to Equation 2. 
3. Results and Discussion 
SOMFA,  a  novel  3D-QSAR  methodology,  is  employed  for  the  analysis  with  the  training  set 
composed of 42 various compounds, from which biological activities are known. Statistical results of 
12 SOMFA models are summarized in Table 3. 
Table 3. Statistics of the various SOMFA models. 
  Rat DHODH  Mouse DHODH 
  All analogues 
Aromatic substituted 
analogues 
Side chain 
3-substituted 
analogues 
All analogues 
Aromatic 
substituted 
analogues 
Side chain 
3-substituted 
analogues 
Align.  1  2  1  2  1  2  1  2  1  2  1  2 
r
2  0.658  0.687  0.758  0.665  0.778  0.897  0.517  0.572  0.554  0.657  0.697  0.859 
rCV
2  0.636  0.664  0.739  0.641  0.715  0.865  0.485  0.545  0.516  0.620  0.610  0.822 
F  98.428  112.251  125.687  79.723  35.180  87.269  52.608  65.608  47.310  72.892  23.106  61.314 
s  0.651  0.623  0.528  0.621  0.604  0.412  0.657  0.619  0.628  0.551  0.590  0.402 
c1  0.695  0.766  0.650  0.769  0.800  0.987  0.531  0.625  0.429  0.660  0.934  0.918 
rpred
2  0.818  0.717  0.571  0.549  0.972  0.981  0.657  0.679  0.512  0.693  0.993  0.991 
r
2, Non cross-validated correlation coefficient; rCV
2, Cross validated correlation coefficient; F, F-test value; s, standard 
error of estimate; c1, mixing coefficient of SOMFA model; rpred
2, Predictive r
2. 
A cross-validated value rCV
2 which is obtained as a result of PLS analysis serves as a quantitative 
measure of the predictability of the SOMFA model. We find that the quality of the QSAR model was 
dependent upon the alignment and number of molecules. The model overlayed using alignment 2 
shows higher rCV
2 values than using the model of alignment 1, and the model of subgroups shows 
higher rCV
2 values than the model of all analogues. 
Among  the  models  tested  from  all  analogues,  good  cross-validated  correlation  coefficient  rCV
2 
values (0.664), moderate non-cross-validated correlation coefficient r
2 values (0.687) proves a good 
conventional  statistical  correlation  which  have  been  obtained,  and  we  also  find  that  the  resultant 
SOMFA model have a satisfying predictive ability. Int. J. Mol. Sci. 2011, 12                       
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The observed and predicted activities of the training set are reported in Table 4. Figure 3 shows a 
satisfying  linear  correlation  and  moderate  difference  between  observed  and  predicted  values  of 
molecules in the training set. 
Table 4. Observed and predicted activities of 42 compounds in the training set. 
Compd 
Rat DHODH  Mouse DHODH 
log(1/IC50)  log(1/IC50) 
Observed  Predicted  Residual
a  Observed  Predicted  Residual
a 
1  5.699  5.846  −0.146  5.801  5.888  −0.088 
2  6.631  6.454  0.175  6.541  6.182  0.358 
3  7.678  7.783  −0.103  7.328  7.385  −0.055 
4  6.320  6.873  −0.553  6.280  6.545  −0.265 
6  6.465  6.772  −0.312  5.523  6.447  −0.927 
7  4.876  5.421  −0.541  4.780  5.501  −0.721 
8  7.102  6.474  0.625  7.444  6.336  1.103 
9  7.276  7.383  −0.103  7.377  7.114  0.265 
11  8.301  8.067  0.232  7.000  6.723  0.277 
12  7.796  6.736  1.063  6.380  5.957  0.422 
13  8.523  8.018  0.501  7.051  6.885  0.164 
14  7.886  7.509  0.380  6.352  6.350  −0.002 
16  6.801  6.923  −0.124  4.821  6.026  −1.206 
17  8.301  7.754  0.545  6.762  6.681  0.079 
18  6.730  6.254  0.475  5.429  5.684  −0.254 
19  5.100  6.006  −0.906  −  −  − 
21  4.660  5.428  −0.768  4.500  5.275  −0.776 
22  7.167  5.759  1.410  5.420  5.450  −0.030 
23  4.851  5.292  −0.442  −  −  − 
24  5.830  6.012  −0.182  5.429  5.703  −0.273 
26  7.854  7.290  0.559  7.260  6.698  0.561 
27  7.398  7.617  −0.217  7.149  6.984  0.165 
28  7.959  8.423  −0.463  6.550  7.119  −0.567 
29  7.4819  7.104  0.375  7.400  6.697  0.703 
31  7.1029  7.043  0.056  6.550  6.543  0.007 
32  7.3019  7.260  0.039  7.201  6.813  0.387 
33  7.553  6.803  0.746  7.444  6.875  0.564 
34  7.959  7.718  0.241  6.750  6.729  0.021 
36  6.200  6.092  0.107  5.599  5.299  0.300 
37  6.530  6.312  0.217  6.201  5.678  0.521 
38  6.229  7.021  −0.791  6.250  6.438  −0.188 
39  4.750  5.469  −0.720  5.301  5.380  −0.081 
41  5.670  5.640  0.030  5.070  5.090  −0.020 
42  5.830  6.735  −0.905  5.801  5.856  −0.055 
43  7.886  7.906  −0.016  7.161  7.431  −0.270 
44  6.550  6.402  0.147  6.680  6.274  0.406 
46  4.750  5.791  −1.041  4.932  5.664  −0.732 
47  4.350  5.299  −0.950  5.100  5.488  −0.388 
48  6.530  6.261  0.268  7.036  6.210  0.826 
49  6.600  6.371  0.229  6.710  6.276  0.434 
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Table 4. Cont. 
Compd 
Rat DHODH  Mouse DHODH 
log(1/IC50)  log(1/IC50) 
Observed  Predicted  Residual
a  Observed  Predicted  Residual
a 
51  6.301  6.505  −0.205  5.680  6.153  −0.473 
52  5.851  6.039  −0.189  5.370  5.743  −0.373 
a Residual = Observed − predicted. 
Figure 3. Observed versus predicted activities (Rat DHODH) in the training set. 
 
It is well known that the best way to validate a 3D-QSAR model is to predict biological activities 
for  the  compounds  forming  the  test  set.  The  SOMFA  analysis  of  the  test  set  composed  of  
11 compounds is reported in Table 5. Most of the compounds in the test set show satisfying correlation 
between  observed  and  predicted  values  in  Figure  4.  We  find  that  two  compounds  of  test  set  
(compound 10 and 15) always have large residuals, and could be classified as outliers. This is true for 
both rat and mouse DHODH models, there may be more complicated structure-activity relationships in 
these two compounds. The statistical parameters rpred
2 of test compounds excluding compound 10 and 15 
are also summarized in Table 3; all the models performed well (rpred
2 > 0.5) in the activity prediction of 
most test compounds. 
SOMFA calculation for both shape and electrostatic potentials are performed, then combined to get 
an optimal coefficient c1 = 0.766 according to Equation 1. The master grid maps derived from the best 
model is used to display the contribution of electrostatic potential and shape molecular field. The 
master grid maps give a direct visual indication of which parts of the compounds differentiate the 
activities of compounds in the training set under study. The master grid also offers an interpretation as 
to how to design and synthesize some novel compounds with much higher activities. The visualization 
of the potential master grid and shape master grid of the best SOMFA model is showed in Figure 5 and 
Figure 6 respectively, with compound 43 as the reference. Int. J. Mol. Sci. 2011, 12                       
 
 
2990 
Table 5. Observed and predicted activities of 11 compounds in the test set. 
Compd 
Rat DHODH  Mouse DHODH 
log(1/IC50)  log(1/IC50) 
Observed  Predicted  Residual
a  Observed  Predicted  Residual
a 
5  7.201  6.882  0.318  7.444  6.569  0.871 
10  5.343  6.928  −1.588  4.429  6.185  −1.755 
15  6.080  7.117  −1.037  4.650  6.340  −1.690 
20  7.678  7.376  0.304  7.301  6.998  0.302 
25  6.801  6.593  0.207  5.951  6.084  −0.134 
30  5.903  5.710  0.190  5.429  5.794  −0.364 
35  7.745  8.034  −0.294  6.750  6.847  −0.097 
40  6.750  6.632  0.118  6.201  5.895  0.305 
45  4.500  5.313  −0.813  4.550  5.392  −0.842 
50  7.638  6.461  1.179  6.750  6.086  0.664 
53  6.971  6.298  0.672  7.201  6.174  1.026 
a Residual = Observed − predicted. 
Figure 4. Observed versus predicted activities (Rat DHODH) in the test set. 
 
Figure 5. The electrostatic potential master grid with compound 43, red represents areas 
where postive potential is favorable, or negative charge is unfavorable, blue represents 
areas  where  negative  potential  is  favorable,  or  postive  charge  is  unfavorable.  (a)  Rat 
DHODH and (b) Mouse DHODH. 
 
(a)  Int. J. Mol. Sci. 2011, 12                       
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Figure 5. Cont. 
 
(b) 
Figure 6. The shape master grid with compound 43, red represents areas of favorable steric 
interaction; blue represents areas of unfavorable steric interaction. (a) Rat DHODH and  
(b) Mouse DHODH. 
 
(a) 
 
(b) 
Each master grid map is colored in two different colors for favorable and unfavorable effects. In 
other words, the electrostatic features are red (more positive charge increases activity, or more negative 
charge decreases activity) and blue (more negative charge increases activity, or more positive charge 
decreases activity), and the shape feature are red (more steric bulk increases activity) and blue (more 
steric bulk decreases activity), respectively. 
It can be seen from Figure 5 and Figure 6 that the electrostatic potential and shape master grid for 
Rat  DHODH  are  very  similar  to  that  for  Mouse  DHODH.  Because  Rat  DHODH  have  structural 
similarities to Mouse DHODH, so active analogues have the same or a similar 3D-QSAR to them.  
SOMFA analysis result indicates the electrostatic contribution is of a low importance (c1 = 0.766). 
In the map of electrostatic potential master grid, we find a high density of blue points around the Int. J. Mol. Sci. 2011, 12                       
 
 
2992 
substituent R1 at the phenyl ring, which means some electronegative groups are favorable. Meanwhile, 
the SOMFA shape potential for the analysis is presented as master grid in Figure 6. In this map of 
important features, we can find a high density of red points around the substituent R1 and R2 at the 
phenyl ring, which means a favorable steric interaction; simultaneously, we also find a high density of 
blue points outside substituent R at the 3-substituted side chain, where an unfavorable steric interaction 
may  be  expected  to  enhance  activities.  Generally,  the  medium-sized  electronegative  potential 
substituent R1 and R2 (benzene ring with electron-withdrawing groups, pyridine ring, for example) at 
the phenyl ring increases the activity, the small-sized substituent R (methyl, ethyl, for example) at the  
3-substituted side chain increases the activity. 
All analyses of SOMFA models may provide some useful information in the design of new active 
metabolite analogues of leflunomide. 
4. Conclusions 
We have developed predictive SOMFA 3D-QSAR models for analogues of the active metabolite of 
Leflunomide as anti-inflammatory drugs. The master grid obtained for the various SOMFA models’ 
electrostatic and shape potential contributions can be mapped back onto structural features relating to the 
trends in activities of the molecules. On the basis of the spatial arrangement of the various electrostatic 
and shape potential contributions, novel molecules are being designed with improved activity. 
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